Using plasma rich in growth factors to treat challenging macular holes
Treatment of Challenging Macular Holes Using Plasma Rich in Growth Factors
This study is testing if a special treatment using growth factor-rich plasma can help close difficult macular holes in people with certain eye conditions.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Minia University Academic / other |
| Locations | 1 site (Minya) |
| Trial ID | NCT06115005 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of plasma rich in growth factors (PRGF) in closing challenging full thickness macular holes (FTMH). It focuses on specific types of FTMH, including recurrent, persistent, and large macular holes in patients with pathological myopia. The methodology involves administering PRGF, which is designed to promote tissue regeneration without the inflammatory effects of leukocytes. The study will assess both structural and visual outcomes following treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with challenging FTMH, such as recurrent or large macular holes.
Not a fit: Patients with corneal opacities, glaucoma, or other significant macular pathologies may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve visual outcomes for patients with difficult-to-treat macular holes.
How similar studies have performed: While the use of PRGF is a novel approach in this context, similar studies have shown promise in other areas of regenerative medicine.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years 2. Challenging FTMH which include Recurrent macular holes Persistent(refractory) macular holes Macular holes in eyes with pathological myopia Large macular holes with an inner diameter of more than 650 µm Exclusion Criteria: * 1-Corneal opacities 2-Glaucomatous patients 3-Co-existing macular pathology ( e.g. diabetic retinopathy, vein occlusion and age related macular degeneration ) 4-History of PPV for any reason other than FTMH
Where this trial is running
Minya
- Minia University Hospital — Minya, Egypt (Recruiting)
Study contacts
- Study coordinator: Zeyad A Askar, Assiss. lect
- Email: zeyadaskar@gmail.com
- Phone: 01060777052
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.